Published in Blood on June 01, 2001
Therapeutic intervention based on protein prenylation and associated modifications. Nat Chem Biol (2006) 1.96
Targeting oncogenic Ras signaling in hematologic malignancies. Blood (2012) 1.67
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood (2006) 1.59
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood (2011) 1.56
Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor. Br J Pharmacol (2004) 1.45
Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer (2004) 1.31
FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta (2007) 1.13
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. J Med Chem (2013) 1.04
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res (2009) 1.04
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab (2011) 1.00
Novel drugs for older patients with acute myeloid leukemia. Leukemia (2014) 0.99
Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia (2014) 0.97
Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neuro Oncol (2005) 0.97
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood (2011) 0.95
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res (2011) 0.95
The clinically relevant pharmacogenomic changes in acute myelogenous leukemia. Pharmacogenomics (2012) 0.94
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res (2008) 0.93
Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting. Front Oncol (2014) 0.93
Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials. Curr Oncol Rep (2008) 0.88
Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. Br J Clin Pharmacol (2006) 0.88
Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood (2011) 0.87
Acute myeloid leukaemia: optimal management and recent developments. Drugs (2011) 0.86
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood (2007) 0.86
Novel targeted drug therapies for the treatment of childhood acute leukemia. Expert Rev Hematol (2009) 0.85
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics (2008) 0.85
A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. Leukemia (2011) 0.85
Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma. Cancer Chemother Pharmacol (2007) 0.84
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer (2014) 0.83
Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels. J Pharmacol Exp Ther (2011) 0.83
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Invest New Drugs (2004) 0.82
Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells. Haematologica (2012) 0.82
Mechanisms of Chromosome Congression during Mitosis. Biology (Basel) (2017) 0.82
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. Br J Cancer (2005) 0.81
Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study. Invest New Drugs (2006) 0.81
Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. Expert Opin Investig Drugs (2010) 0.81
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group. Pediatr Blood Cancer (2010) 0.80
Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica (2013) 0.79
Farnesyl transferase inhibitor resistance probed by target mutagenesis. Blood (2007) 0.79
Treatment concepts for elderly patients with acute myeloid leukemia. Wien Klin Wochenschr (2003) 0.79
The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). Cancers (Basel) (2012) 0.78
Tipifarnib in the treatment of acute myeloid leukemia. Biologics (2007) 0.78
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. Blood (2015) 0.77
Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. Clin Cancer Res (2014) 0.77
The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution. BMC Pharmacol (2002) 0.76
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor. Br J Cancer (2004) 0.76
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res (2013) 0.76
Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells. J Cancer Res Clin Oncol (2011) 0.75
In Vitro Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells. Transl Med UniSa (2016) 0.75
[Risk-adapted therapy of acute myeloid leukemia]. Internist (Berl) (2006) 0.75
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell (1993) 11.95
Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature (1994) 10.22
Sulfolobus: a new genus of sulfur-oxidizing bacteria living at low pH and high temperature. Arch Mikrobiol (1972) 9.81
The role of cell-mediated immunity in bacterial infections. Rev Infect Dis (1982) 9.26
Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet (1990) 8.56
Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem (1999) 8.16
Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell (1985) 7.29
Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature (1991) 5.51
Crystal structure of cyclin-dependent kinase 2. Nature (1993) 5.21
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer (2000) 4.96
Interaction of human Arp2/3 complex and the Listeria monocytogenes ActA protein in actin filament nucleation. Science (1998) 4.74
Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell (1996) 4.74
Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology (1991) 4.47
Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J (1992) 4.21
Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science (1989) 4.19
CD8+ T lymphocytes in intracellular microbial infections. Immunol Today (1988) 4.12
Protection of mice against the intracellular bacterium Listeria monocytogenes by recombinant immune interferon. Eur J Immunol (1984) 4.00
Propagation of both parental mitochondrial DNAs in rat-human and mouse-human hybrid cells. J Mol Biol (1973) 3.93
A recombinant 64 kilodalton protein of Mycobacterium bovis bacillus Calmette-Guerin specifically stimulates human T4 clones reactive to mycobacterial antigens. J Exp Med (1986) 3.92
Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Infect Immun (1987) 3.87
Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. J Immunol (1987) 3.68
Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest (2000) 3.58
Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. Infect Immun (1991) 3.54
Biological functions of t cell lines with specificity for the intracellular bacterium Listeria monocytogenes in vitro and in vivo. J Exp Med (1982) 3.52
Different roles of alpha beta and gamma delta T cells in immunity against an intracellular bacterial pathogen. Nature (1993) 3.47
Involvement of profilin in the actin-based motility of L. monocytogenes in cells and in cell-free extracts. Cell (1994) 3.42
Mycobacterial protein antigens: a compilation. Mol Microbiol (1992) 3.35
Activation of tuberculostatic macrophage functions by gamma interferon, interleukin-4, and tumor necrosis factor. Infect Immun (1990) 3.35
Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol (1995) 3.34
Specific Lyt 123 cells are involved in protection against Listeria monocytogenes and in delayed-type hypersensitivity to listerial antigens. J Exp Med (1979) 3.31
Immune responses in interleukin-2-deficient mice. Science (1993) 3.29
Mechanism of the t(14;18) chromosomal translocation: structural analysis of both derivative 14 and 18 reciprocal partners. Proc Natl Acad Sci U S A (1987) 3.18
Immune response to infection with Salmonella typhimurium in mice. J Leukoc Biol (2000) 2.99
Salmonella typhimurium aroA- infection in gene-targeted immunodeficient mice: major role of CD4+ TCR-alpha beta cells and IFN-gamma in bacterial clearance independent of intracellular location. J Immunol (1996) 2.97
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia (2009) 2.94
Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution. Proc Natl Acad Sci U S A (1995) 2.89
Mycobacteria-reactive Lyt-2+ T cell lines. Eur J Immunol (1988) 2.88
Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med (1995) 2.80
T cells against a bacterial heat shock protein recognize stressed macrophages. Science (1989) 2.79
Assessment of aldehyde dehydrogenase in viable cells. Blood (1995) 2.77
A purified Drosophila septin complex forms filaments and exhibits GTPase activity. J Cell Biol (1996) 2.76
Effective protection against Listeria monocytogenes and delayed-type hypersensitivity to listerial antigens depend on cooperation between specific L3T4+ and Lyt 2+ T cells. Infect Immun (1985) 2.70
Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev (1999) 2.69
Actin dynamics in vivo. Curr Opin Cell Biol (1997) 2.58
T- and B-lymphocyte-independent formation of alveolar macrophage-derived multinucleated giant cells in murine Pneumocystis carinii pneumonia. Infect Immun (1996) 2.55
Immune response to Mycobacterium bovis bacille Calmette Guérin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur J Immunol (1995) 2.48
The role of T-cell subsets and cytokines in the regulation of infection. Immunol Today (1991) 2.48
Detection and differentiation of fungi in clinical specimens using polymerase chain reaction (PCR) amplification and restriction enzyme analysis. J Med Vet Mycol (1993) 2.47
Immune responses to Yersinia enterocolitica in susceptible BALB/c and resistant C57BL/6 mice: an essential role for gamma interferon. Infect Immun (1994) 2.45
Enumeration of T cells reactive with Mycobacterium tuberculosis organisms and specific for the recombinant mycobacterial 64-kDa protein. Eur J Immunol (1987) 2.45
Listeria monocytogenes-reactive T lymphocyte clones with cytolytic activity against infected target cells. J Exp Med (1986) 2.42
Studies with MHC-deficient knock-out mice reveal impact of both MHC I- and MHC II-dependent T cell responses on Listeria monocytogenes infection. J Immunol (1994) 2.39
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol (1999) 2.38
A large fraction of human peripheral blood gamma/delta + T cells is activated by Mycobacterium tuberculosis but not by its 65-kD heat shock protein. J Exp Med (1990) 2.37
Differential T cell responses to Mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors. Eur J Immunol (1998) 2.35
The role of proteases during apoptosis. FASEB J (1996) 2.35
Protective role of gamma/delta T cells and alpha/beta T cells in tuberculosis. Eur J Immunol (1995) 2.34
Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest (1999) 2.32
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet (2000) 2.31
Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect Immun (1997) 2.31
Cleavage of lamin A by Mch2 alpha but not CPP32: multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proc Natl Acad Sci U S A (1996) 2.31
PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci U S A (1994) 2.29
Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens. Mol Microbiol (1999) 2.28
Primary responses of human T cells to mycobacteria: a frequent set of gamma/delta T cells are stimulated by protease-resistant ligands. Eur J Immunol (1990) 2.25
Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat Biotechnol (1998) 2.25
Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest (1992) 2.25
Caspases and caspase inhibitors. Trends Biochem Sci (1997) 2.17
Analysis of gene-specific DNA damage and repair using quantitative polymerase chain reaction. Methods (2000) 2.16
Ecology of iron-oxidizing bacteria in pyritic materials associated with coal. J Bacteriol (1974) 2.12
Interferon-gamma production by Listeria monocytogenes-specific T cells active in cellular antibacterial immunity. Eur J Immunol (1983) 2.06
Dysgonic fermenter 3-associated gastrointestinal disease in a patient with common variable hypogammaglobulinemia. Am J Med (1988) 2.05
Early events in hepatitis C virus infection of chimpanzees. Proc Natl Acad Sci U S A (1990) 2.04
Antigen-specific Lyt-2+ cytolytic T lymphocytes from mice infected with the intracellular bacterium Listeria monocytogenes. J Immunol (1986) 2.04
Alterations in insulin binding accompanying differentiation of 3T3-L1 preadipocytes. Proc Natl Acad Sci U S A (1977) 2.01
Considerations in the isolation of rat liver nuclear matrix, nuclear envelope, and pore complex lamina. Exp Cell Res (1981) 1.99
Fungicidal activity of IFN-gamma-activated macrophages. Extracellular killing of Cryptococcus neoformans. J Immunol (1989) 1.97
Acquired resistance to facultative intracellular bacteria: relationship between persistence, cross-reactivity at the T-cell level, and capacity to stimulate cellular immunity of different Listeria strains. Infect Immun (1984) 1.96
Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia (2006) 1.95
Studies in relation to biosynthesis. XLII. The structural elucidation and some aspects of the biosynthesis of the brevianamides-A and -E. Tetrahedron (1970) 1.95
T lymphocytes from healthy individuals with specificity to self-epitopes shared by the mycobacterial and human 65-kilodalton heat shock protein. J Immunol (1989) 1.94
The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst (1993) 1.84
IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol (1999) 1.83
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res (1996) 1.82
Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood (1998) 1.80
Attempts to characterize the mechanisms involved in mycobacterial growth inhibition by gamma-interferon-activated bone marrow macrophages. Infect Immun (1988) 1.80
Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis. J Exp Med (1997) 1.77
Characterization of the major polypeptides of the rat liver nuclear envelope. J Biol Chem (1983) 1.75
Immune responses to intracellular bacteria. Curr Opin Immunol (2001) 1.75
Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies. Bioinformatics (2004) 1.72
Target cell lysis and IL-2 secretion by gamma/delta T lymphocytes after activation with bacteria. J Immunol (1990) 1.71
Sources of nonlinearity in cDNA microarray expression measurements. Genome Biol (2001) 1.70
Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood (1996) 1.70
Rapid neutrophil response controls fast-replicating intracellular bacteria but not slow-replicating Mycobacterium tuberculosis. J Infect Dis (2000) 1.68
Growth inhibition of Mycobacterium bovis by IFN-gamma stimulated macrophages: regulation by endogenous tumor necrosis factor-alpha and by IL-10. Int Immunol (1994) 1.68
Effective antibacterial protection induced by a Listeria monocytogenes-specific T cell clone and its lymphokines. Infect Immun (1983) 1.68
Iron overload in beta 2-microglobulin-deficient mice. Immunol Lett (1994) 1.67
Increased numbers of ESAT-6- and purified protein derivative-specific gamma interferon-producing cells in subclinical and active tuberculosis infection. Infect Immun (2000) 1.67
Single-strand conformation polymorphism and heteroduplex analysis for gel-based mutation detection. Electrophoresis (1999) 1.66
Immunity against intracellular bacteria: biological effector functions and antigen specificity of T lymphocytes. Curr Top Microbiol Immunol (1988) 1.65